Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide
Kailun He, Zhuo Zhang, Wenbing Wang, Xiaoliang Zheng, Xiaoju Wang, Xingxian Zhang
Topics & Concepts
OsimertinibChemistryEpidermal growth factor receptorProteolysisCytotoxicityDrug discoveryIC50Cell cultureIn vitroPharmacologyReceptorBiochemistryBiologyEnzymeErlotinibGeneticsProtein Degradation and InhibitorsMultiple Myeloma Research and TreatmentsPeptidase Inhibition and Analysis